DBV Technologies’ peanut allergy vaccine missed the mark—by a whisker—in a phase 3 trial but is still at least 50:50 for FDA approval, say analysts at Jefferies. Top-line data from the PEPITES study showed that the Viaskin Peanut patch-based therapy showed a statistically significant improvement over placebo, but the difference wasn’t quite enough to meet the level of efficacy intended to support FDA approval. There is still no FDA-approved treatment for peanut allergy, which causes thousands of people to be admitted to the emergency room each year in the U.S. with anaphylactic reactions and—by some estimates—accounts for upwards of 50% of the 100-200 annual fatalities caused by allergies.

Read More at FierceBiotech